VXRT Company Profile and Key Details

The latest quarter delivered EPS of -$0.04. The next quarter is forecast at -$0.10. Next year's EPS is expected at $17.03. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $2.00 to $2.00. The high target offers 166.67% upside. The low target suggests 166.67% downside. The mean target is $2.00. This offers 166.67% upside. Vaxart, Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by -42.86%. The prior quarter beat by -22.22%. Over the last six quarters, Apple has recorded several small beats. These include 233.33% in August 08, 2024.

VXRT has shown sold momentum, gaining 25.71% over the past week and 23.53% over the past quarter, though year-to-date performance is down -33.54%. Short-term trend indicators are mixed aligned (SMA20 -37.07%, SMA50 -30.91%, SMA200 -46.7%). The stock’s 14-day RSI is 31.56 (weak momentum), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -70.09% below its high and over 12.28% above its low. Average 10-day trading volume of 467.37 thousand shares is slightly above the 3-month average of 382.42 thousand, indicating heightened recent market interest.

Vaxart, Inc. has 228.92 million shares outstanding. The public float is 226.74 million shares, elevated short interest at 9.40% of float. This equals 21.17 million shares. The short ratio is 2.61 days. Institutional investors hold 17.96% of the float. Insiders own 0.87%. Finney Michael J. holds 181.82 thousand shares, Finney Kevin has 154.77 thousand shares and ARMISTICE CAPITAL, LLC has 145.52 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Vaxart, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.38. This means the shares are trading below this model’s fair value.

Vaxart, Inc. (NASDAQ:VXRT) closed at $0.76 USD, gaining $0.01 (1.33%) from the previous close of $0.75. The stock is currently mid-range between its 52-week high and low $0.26 and $0.84. With a market capitalization of about $182.45 million, Vaxart, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.24). Key stats such as the average daily volume over the past year has been around 841.07 thousand shares, volume is running light vs its 52-week average. Headquartered in South San Francisco, CA, Vaxart, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Steven Lo, the company employs approximately 105 people and listed since December 11, 1981. Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.

Vaxart, Inc. trades at a P/E ratio of -3.3, slightly below the S&P 500 average, with a price-to-sales ratio of 1.18 and a price-to-book ratio of 6.25 trading at moderately above to book value. The P/FCF stands at -5.75, also below market averages.

Our AI price prediction model suggests that Vaxart, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected rise of 61.33%, reaching $1.21 by June 01, 2026, with a range of $1.18 to $1.24. 1-Year Outlook: Projected gain of 2746.67%, with price at $21.35 by March 03, 2027, within a range of $13.69 to $30.43.

Vaxart, Inc. (NASDAQ:VXRT) shares are down -33.54% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Vaxart, Inc. trading at a premium to the broader market with a P/E of -3.3. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.96, suggesting 1228.0% upside.